Multi-unit ribozyme inhibition of oncogene gene expression
US5635385A · kind A · utility
33Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 1993 |
| Grant date | Jun 3, 1997 |
| Priority date | — |
| Expiry date | Sep 15, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel multi-unit ribozyme is provided which is capable of selectively cleaving the mRNA transcript of a hybrid oncogene resulting from a chromosomal translocation. Specialized delivery vehicles such as liposomes, and growth factor conjugates for cellular uptake by receptor-mediated endocytosis, are also described. The multi-unit ribozyme is used for the treatment of neoplasms characterized by expression of the oncogene. In one embodiment, a multi-unit ribozyme is provided which cleaves the mRNA transcript of Philadelphia chromosome-positive cells, thereby blocking production of the tumorigenic p210.sup.bcr-abl fusion protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.